- No file added yet -
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial
media
posted on 2021-01-26, 16:59 authored by Adis journals on behalf of, Kim A. Papp, Saskia de Vente, Jiewei Zeng, Mary Flack, Byron Padilla, Stephen K. TyringArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
